MedTrace Logo

Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer

NCT03192059 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2021-09-08

No results posted yet for this study

Summary

This is a Phase II study in patients with advanced and/refractory cervical cancer, endometrial carcinoma or uterine sarcoma.

Patients will be treated with an immunomodulatory cocktail (Vitamin D, aspirin, Cyclophosphamide and Lansoprazole), followed by pembrolizumab, combined with radiation. In addition, patients will take Curcumin, a food supplement.

Conditions

Interventions

DRUG

Pembrolizumab

Efficacy of the combined treatment

RADIATION

Radiation

Efficacy of the combined treatment

DRUG

Vitamin D

Efficacy of the combined treatment

DRUG

Aspirin

Efficacy of the combined treatment

DRUG

Lansoprazole

Efficacy of the combined treatment

DRUG

Cyclophosphamide

Efficacy of the combined treatment

DIETARY_SUPPLEMENT

Curcumin

Efficacy of the combined treatment

Sponsors & Collaborators

  • Kom Op Tegen Kanker

    collaborator OTHER

  • Anticancer Fund, Belgium

    collaborator OTHER

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Hannelore Denys, MD, PhD · University Hospital, Ghent

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03192059 on ClinicalTrials.gov